Business
Trading Update
Trading Update.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n\n \n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.\n \n30 November 2023\n \n\n \nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\")\n \nTrading update for the year 2023\n \nThe Company announces a trading update to its shareholders.\n \nThe Company expects the US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory. The Company is also engaged in discussions with several pharmaceutical companies and academic groups regarding single cell proteomics projects and hope to initiate studies early in 2024. \n \nHowever, the Company now expects to report reduced revenues for the full year 2023, which will be lower than FY 2022. As reported by many other life science technology providers, the Company has experienced delays to projects, many of which have been postponed to 2024. The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year. In addition to other topical macro-economic headwinds, the Company has seen that the biopharma clients have been restrictive on R&D outsourcing expenditure through contract research organisations.\n \nReduced revenues combined with the commitment to invest for the future by opening the Company's US laboratory, developing and commercial launch of Single Cell Proteomics, and the development of next generation tags, means the Company expects to post a net loss for the full year 2023.\n \nFor 2024 the Company expects a more positive environment for services evidenced by increased customer activity in recent weeks and based on the expectation that an improved macro-economic environment will drive renewed investment into drug development at more traditional levels and that delayed projects will be commissioned.\n \n \nProteome Sciences plc \n\n\n\n\nDr. Mariola Soehngen, Chief Executive Officer\nDr. Ian Pike, Chief Scientific Officer\n\n\nTel: +44 (0)20 7043 2116\n\n\n\n\nRichard Dennis, Chief Commercial Officer\nAbdelghani Omari, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAllenby Capital Limited (Nominated A...